Louis Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louis Williams has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Eileen Mary Boyle
Myeloma Research Program, NYU Langone, Perlmutter Cancer Center
182 shared publications - Faith E. Davies
Perlmutter Cancer Center, NYU Langone Health, New York, NY
182 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
182 shared publications - James H. Stoeckle
Dana-Farber Brigham Cancer Center, South Weymouth, MA
182 shared publications - Alexander Li
Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York
181 shared publications - Ariel Siegel
Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York
181 shared publications
Latest Publications
- Open Access
Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by a heterogeneous risk of progression to overt multiple myeloma (MM). Historically managed with active surveillance, advances in risk stratification and the development of novel therapeutics have renewed debate regarding early intervention, particularly in patients with high-risk disease. We conducted a narrative review of clinical trials and observational studies evaluating early treatment versus observation in SMM. Outcomes assessed included progression-free survival (PFS), time to progression (TTP), overall survival (OS), treatment-related toxicity, and quality-of-life measures, alongside evolving diagnostic criteria and risk-stratification models that influence therapeutic decision-making. Early randomized trials using conventional cytotoxic therapy did not demonstrate a survival advantage and supported observation as the standard management approach. However, contemporary studies using novel agents have demonstrated improved disease control in selected high-risk populations. The QuiRedex and ECOG-E3A06 trials showed significant reductions in progression risk with lenalidomide-based therapy, and long-term follow-up suggests a potential overall survival benefit in Qui-Redex. The phase III AQUILA trial further demonstrated delayed progression with daratumumab in high-risk SMM using updated diagnostic criteria. Phase II studies evaluating combination regimens, including KRd-based and daratumumab-containing approaches, have reported high response rates and MRD negativity, although survival data remain immature. Importantly, many benefits reflect delayed biochemical or imaging-defined progression rather than prevention of symptomatic end-organ damage. Current evidence supports selective early intervention in carefully defined high-risk SMM populations; however, uncertainties remain regarding long-term survival benefit, optimal treatment duration, quality-of-life impact, and clonal evolution. Active surveillance with modern monitoring remains appropriate for many patients.
Open AccessSmoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by a heterogeneous risk of progression to overt multiple myeloma (MM). Historically managed with active surveillance, advances in risk stratification and the development of novel therapeutics have renewed debate regarding early intervention, particularly in patients with high-risk disease. We conducted a narrative review of clinical trials and observational studies evaluating early treatment versus observation in SMM. Outcomes assessed included progression-free survival (PFS), time to progression (TTP), overall survival (OS), treatment-related toxicity, and quality-of-life measures, alongside evolving diagnostic criteria and risk-stratification models that influence therapeutic decision-making. Early randomized trials using conventional cytotoxic therapy did not demonstrate a survival advantage and supported observation as the standard management approach. However, contemporary studies using novel agents have demonstrated improved disease control in selected high-risk populations. The QuiRedex and ECOG-E3A06 trials showed significant reductions in progression risk with lenalidomide-based therapy, and long-term follow-up suggests a potential overall survival benefit in Qui-Redex. The phase III AQUILA trial further demonstrated delayed progression with daratumumab in high-risk SMM using updated diagnostic criteria. Phase II studies evaluating combination regimens, including KRd-based and daratumumab-containing approaches, have reported high response rates and MRD negativity, although survival data remain immature. Importantly, many benefits reflect delayed biochemical or imaging-defined progression rather than prevention of symptomatic end-organ damage. Current evidence supports selective early intervention in carefully defined high-risk SMM populations; however, uncertainties remain regarding long-term survival benefit, optimal treatment duration, quality-of-life impact, and clonal evolution. Active surveillance with modern monitoring remains appropriate for many patients.
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (5) , 365
Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up
Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up
- 1 May 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (5) , 365
Open AccessFully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up
Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Methylation probe intensity across chromosome 1. Heatmap representation of the beta value for all probes across chromosome 1, the probes a presented in a genomic coordinate sorted fashion. The recurrent regions of deletion, gain, templated insertion, and chromothripsis have be highlighted along with the cytoband information for reference.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Methylation probe intensity across chromosome 1. Heatmap representation of the beta value for all probes across chromosome 1, the probes a presented in a genomic coordinate sorted fashion. The recurrent regions of deletion, gain, templated insertion, and chromothripsis have be highlighted along with the cytoband information for reference.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Common dependency pathway analysis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Common dependency pathway analysis
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of copy number gain and loss together with the candidate genes located within the regions.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of copy number gain and loss together with the candidate genes located within the regions.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Genes with increased dependency in cell lines with del(1p) [part A] Genes with increased dependency in cell lines with del(1p) [part B]
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Genes with increased dependency in cell lines with del(1p) [part A] Genes with increased dependency in cell lines with del(1p) [part B]
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of chromothripsis and chromoplexy together with the candidate genes located within the regions. A. CHromothripsis B. Templated Instertion
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Recurrent regions of chromothripsis and chromoplexy together with the candidate genes located within the regions. A. CHromothripsis B. Templated Instertion
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
List of known tumour suppressor genes significantly under expressed in patients identified as having del(1p) in RNA-seq data from the CoMMpass dataset. A. Del(1p12): Using copy number loss of TENT5C to identify cases. B. Del(1p22.1): Using copy number loss of RPL5 to identify cases.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
List of known tumour suppressor genes significantly under expressed in patients identified as having del(1p) in RNA-seq data from the CoMMpass dataset. A. Del(1p12): Using copy number loss of TENT5C to identify cases. B. Del(1p22.1): Using copy number loss of RPL5 to identify cases.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Chromatin state of different SV regions. The CT1 region at 1p36.11-1p34.3 is comprised of greater than 74% A-compartment (range 74-100%); CT2 at 1p33-1p32.3 comprises both inactive (range 35-59%) and active chromatin (range 41-65%) and, CT3 at 1p13.3-1p12, overlaps with TI1, had greater variability with 86% A-compartment in U266 while only 1% in KMS11. TI1 region predominantly laid in B-compartment (range 63-73%) and TI2 lay in an almost entirely active compartment (range 91-100%). NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Chromatin state of different SV regions. The CT1 region at 1p36.11-1p34.3 is comprised of greater than 74% A-compartment (range 74-100%); CT2 at 1p33-1p32.3 comprises both inactive (range 35-59%) and active chromatin (range 41-65%) and, CT3 at 1p13.3-1p12, overlaps with TI1, had greater variability with 86% A-compartment in U266 while only 1% in KMS11. TI1 region predominantly laid in B-compartment (range 63-73%) and TI2 lay in an almost entirely active compartment (range 91-100%). NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.